Related Experiment Video
Updated: Apr 29, 2026
06:01
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
1.3K
Reduced membranous MET expression is linked to bladder cancer progression
Martina Kluth1, Kristina Reynolds1, Michael Rink2
1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cancer Genetics
|May 24, 2014
Summary
MET protein expression in bladder cancer is often downregulated, not overexpressed, and not linked to gene amplification or poor clinical outcomes. Low MET staining correlates with unfavorable tumor phenotypes.
Area of Science:
- Oncology
- Molecular Biology
- Urothelial Carcinomas
Background:
- The MET protein tyrosine kinase receptor plays a role in tumor progression.
- Understanding MET expression in bladder cancer is crucial for therapeutic strategies.
Purpose of the Study:
- To investigate MET protein expression in bladder cancer.
- To correlate MET expression with tumor phenotype and clinical outcomes.
- To determine the role of MET gene amplification in overexpression.
Main Methods:
- Analysis of a bladder cancer tissue microarray (686 samples) using immunohistochemistry and fluorescence in situ hybridization.
- Assessment of MET immunostaining in normal urothelium and various tumor grades and stages.
- Evaluation of MET gene amplification status.
Main Results:
- MET immunostaining was observed in 82.0% of urothelial carcinomas.
- Lower MET staining was associated with unfavorable tumor phenotypes and decreased with higher tumor grade and stage.
- MET expression was not linked to survival, tumor progression, or recurrence.
- MET gene amplification was rare (0.8%) and not associated with overexpression.
Conclusions:
- MET protein is frequently expressed but often downregulated in bladder cancer, not overexpressed.
- MET gene amplification is uncommon and does not drive protein overexpression.
- MET expression levels do not predict clinical outcomes in bladder cancer.
